Next Article in Journal
NS1 Antigenemia and Viraemia Load: Potential Markers of Progression to Dengue Fatal Outcome?
Previous Article in Journal
Production of Bacteriophages by Listeria Cells Entrapped in Organic Polymers
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessArticle
Viruses 2018, 10(6), 325; https://doi.org/10.3390/v10060325

A Simple and Robust Approach for Evaluation of Antivirals Using a Recombinant Influenza Virus Expressing Gaussia Luciferase

1
College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
2
Shandong Provincial Collaborative Innovation Center for Antiviral Traditional Chinese Medicine, Jinan 250355, China
3
College of Traditional Chinese medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
4
Department of Microbiology, University of Chicago, Chicago, IL 60637, USA
5
Scientific Research Centre, College of Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
6
Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA
*
Author to whom correspondence should be addressed.
Received: 16 May 2018 / Revised: 9 June 2018 / Accepted: 11 June 2018 / Published: 13 June 2018
(This article belongs to the Section Animal Viruses)
Full-Text   |   PDF [1374 KB, uploaded 13 June 2018]   |  

Abstract

Influenza A virus (IAV) causes seasonal epidemics and occasional but devastating pandemics, which are major public health concerns. Because the effectiveness of seasonal vaccines is highly variable and the currently available drugs are limited in their efficacy because of the emergence of drug resistance, there is an urgent need to develop novel antivirals. In this study, we characterized a recombinant IAV-carrying Gaussia luciferase (Gluc) gene and determined its potential as a tool for evaluating therapeutics. We demonstrated that this recombinant IAV is replication-competent in tissue culture and pathogenic in mice, although it is slightly attenuated compared to the parental virus. Luciferase expression correlated well with virus propagation both in vitro and in vivo, providing a simple measure for viral replication in tissue culture and in mouse lungs. To demonstrate the utility of this virus, ribavirin and oseltamivir phosphate were used to treat the IAV-infected cells and mice, and we observed the dose-dependent inhibition of viral replication by a luciferase assay. Moreover, the decreased luciferase expression in the infected lungs could predict the protective efficacy of antiviral interventions as early as day 2 post virus challenge. In summary, this study provides a new and quantitative approach to evaluate antivirals against IAV. View Full-Text
Keywords: influenza A virus; Gaussia luciferase; antiviral; therapeutics influenza A virus; Gaussia luciferase; antiviral; therapeutics
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Li, P.; Cui, Q.; Wang, L.; Zhao, X.; Zhang, Y.; Manicassamy, B.; Yang, Y.; Rong, L.; Du, R. A Simple and Robust Approach for Evaluation of Antivirals Using a Recombinant Influenza Virus Expressing Gaussia Luciferase. Viruses 2018, 10, 325.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top